Sarcoidosis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Sarcoidosis Classification and external resources | |
| Sarcoidosis in a Lymph Node. | |
| ICD-10 | D86. |
| ICD-9 | 135 |
| OMIM | 181000 |
| DiseasesDB | 11797 |
| MedlinePlus | 000076 |
| eMedicine | med/2063 |
| MeSH | D012507 |
|
WikiDoc Resources for Sarcoidosis | |
|
Articles | |
|---|---|
|
Most recent articles on Sarcoidosis Most cited articles on Sarcoidosis | |
|
Media | |
|
Powerpoint slides on Sarcoidosis | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Sarcoidosis at Clinical Trials.gov Clinical Trials on Sarcoidosis at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Sarcoidosis
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Sarcoidosis Discussion groups on Sarcoidosis Patient Handouts on Sarcoidosis Directions to Hospitals Treating Sarcoidosis Risk calculators and risk factors for Sarcoidosis
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Sarcoidosis | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Phone:617-525-6884
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [3] Phone:617-525-7431
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
for the heart in Sarcoidosis click here
Overview
Sarcoidosis, also called sarcoid (from the Greek 'sark' and 'oid' meaning "flesh-like") or Besnier-Boeck disease, is an immune system disorder characterised by non-caseating granulomas (small inflammatory nodules) that most commonly arises in young adults. The cause of the disease is still unknown. Virtually any organ can be affected; however, granulomas most often appear in the lungs (D86.0) or the lymph nodes (D86.1). Symptoms can occasionally appear suddenly but usually appear gradually. The clinical course varies and ranges from asymptomatic disease that resolves spontaneously to a debilitating chronic condition that may lead to death.
Epidemiology
Sarcoidosis most commonly affects young adults of both sexes, with a slight preponderance for women having been reported by most studies. Incidence is highest for individuals younger than 40 and peaks in the age-group from 20 to 29 years.[1]
Sarcoidosis occurs throughout the world in all races with a prevalence ranging from 1 to 40 per 100,000. The disease is most prevalent in Northern European countries, and the highest annual incidence of 60 per 100,000 is found in Sweden and Iceland. In the United States, sarcoidosis is more common in people of African descent than Caucasians, with annual incidence reported as 35.5 and 10.9 per 100,000, respectively.[1] Sarcoidosis is less commonly reported in South America, Spain and India.
The differing incidence across the world may be at least partially attributable to the lack of screening programs in certain regions of the world and the overshadowing presence of other granulolomatous diseases such as tuberculosis, that may interfere with the diagnosis of sarcoidosis where they are prevalent.[1]
There may also be racial differences in the severity of the disease. Several studies suggest that the presentation in people of African origin may be more severe than for Caucasians, who are more likely to suffer from asymptomatic disease.[1]
Signs and symptoms
Sarcoidosis is a Systemic Disease that can affect any organ. Common symptoms are vague, such as fatigue unchanged by sleep, lack of energy, weight loss, aches and pains, arthralgia, dry eyes, blurry vision, shortness of breath, a dry hacking cough or skin lesions. The cutaneous symptoms vary, and range from rashes and noduli (small bumps) to erythema nodosum or lupus pernio. It is often asymptomatic.
The combination of erythema nodosum, bilateral hilar lymphadenopathy and arthralgia is called Lofgren syndrome. This syndrome has a relatively good prognosis.
Renal, liver (including portal hypertension), heart or brain involvement may cause further symptoms and altered functioning. Manifestations in the eye include uveitis and retinal inflammation, which may result in loss of visual acuity or blindness. Sarcoidosis affecting the brain or nerves is known as neurosarcoidosis.
The combination of anterior uveitis, parotitis and fever is called uveoparotitis, and is associated with Heerfordt-Waldenstrom syndrome. (D86.8)
Investigations
Hypercalcemia (high calcium levels) and its symptoms may be the result of excessive vitamin D activation.
Sarcoidosis most often manifests as a restrictive disease of the lungs, causing a decrease in lung volume and decreased compliance (the ability to stretch). The disease typically limits the amount of air drawn into the lungs, but produces higher than normal expiratory flow ratios. The vital capacity (full breath in, to full breath out) is decreased, and most of this air can be blown out in the first second. This means the FEV1/FVC ratio is increased from the normal of about 80%, to 90%. Obstructive lung changes, causing a decrease in the amount of air that can be exhaled, may occur when enlarged lymph nodes in the chest compress airways or when internal inflammation or nodules impede airflow.
Chest X-ray changes are divided into five stages
- Stage 0 Negative chest radiograph
- Stage 1 bihilar lymphadenopathy
- Stage 2 Hilar lymphadenopathy and reticulonodular pulmonary infiltrates
- Stage 3 bilateral infiltrates
- Stage 4 fibrocystic sarcoidosis typically with upward hilar retraction, cystic & bullous changes
Because sarcoidosis can affect multiple organ systems, follow-up on a patient with sarcoidosis should always include an electrocardiogram, ophthalmologic exam, liver function tests, serum calcium and 24-hour urine calcium.
Causes and pathophysiology
No direct cause of sarcoidosis has been identified, although there have been reports of cell wall deficient bacteria that may be possible pathogens.[1] These bacteria are not identified in standard laboratory analysis. It has been thought that there may be a hereditary factor because some families have multiple members with sarcoidosis. To date, no reliable genetic markers have been identified, and an alternate hypothesis is that family members share similar exposures to environmental pathogens. There have also been reports of transmission of sarcoidosis via organ transplants.[1]
Sarcoidosis frequently causes a dysregulation of vitamin D production with an increase in extrarenal (outside the kidney) production.[1] Specifically, macrophages inside the granulomas convert vitamin D to its active form, resulting in elevated levels of the hormone 1,25-dihydroxyvitamin D and symptoms of hypervitaminosis D that may include fatigue, lack of strength or energy, irritability, metallic taste, temporary memory loss or cognitive problems. Physiological compensatory responses (e.g. suppression of the parathyroid hormone levels) may mean the patient does not develop frank hypercalcemia.
Sarcoidosis has been associated with celiac disease. Celiac disease is a condition in which there is a chronic reaction to certain protein chains, commonly referred to as glutens, found in some cereal grains. This reaction causes destruction of the villi in the small intestine, with resulting malabsorption of nutrients.
While disputed, some cases have been determined to be caused by inhalation of the dust from the collapse of the World Trade Center after the September 11, 2001 attacks.[1] See Health effects arising from the September 11, 2001 attacks for more information.
Gallium-67 citrate is useful for diagnosing suspected sarcoidosis and evaluation of treatment response. It is more sensitive than radiographic images on diagnosis of Sarcoidosis.
Image Examples
Treatment
Corticosteroids, most commonly prednisone, have been the standard treatment for many years. In some patients, this treatment can slow or reverse the course of the disease, but other patients unfortunately do not respond to steroid therapy. The use of corticosteroids in mild disease is controversial because in many cases the disease remits spontaneously. Additionally, corticosteroids have many recognized dose- and duration-related side effects (which can be reduced through the use of alternate-day dosing for those on chronic prednisone therapy [1]), and their use is generally limited to severe, progressive, or organ-threatening disease. The influence of corticosteroids or other immunosuppressants on the natural history is unclear.
Severe symptoms are generally treated with steroids, and steroid-sparing agents such as azathioprine and methotrexate are often used. Rarely, cyclophosphamide has also been used. As the granulomas are caused by collections of immune system cells, particularly T cells, there has been some early indications of success using immunosuppressants, interleukin-2 inhibitors or anti-tumor necrosis factor-alpha treatment (such as infliximab). Unfortunately, none of these have provided reliable treatment and there can be significant side effects such as an increased risk of reactivating latent tuberculosis.
Avoidance of sunlight and Vitamin D foods may be helpful in patients who are susceptible to developing hypercalcemia.
See also
References
External links
- The Foundation for Sarcoidosis Research
- Pathology Images of Sarcoidosis and Other Granulomatous Diseases
- Microscopy of granulomas in sarcoidosis
- Kveim test at GPnotebook
- The Sarcoidosis Community is The Foundation for Sarcoidosis Research's online community
- Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease
- MedPix Pulmonary Sarcoid
WikiDoc Research Resources for Sarcoidosis | |
|---|---|
| Articles on Sarcoidosis | Most recent articles on Sarcoidosis • Most cited articles on Sarcoidosis • Review articles on Sarcoidosis • Articles on Sarcoidosis in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Sarcoidosis | Powerpoint slides on Sarcoidosis • Images of Sarcoidosis • Photos of Sarcoidosis • Podcasts & MP3s on Sarcoidosis • Videos on Sarcoidosis |
| Evidence Based Medicine Regarding Sarcoidosis | Cochrane Collaboration on Sarcoidosis • Bandolier on Sarcoidosis • TRIP on Sarcoidosis |
| Cost Effectiveness of Sarcoidosis | Cost Effectiveness of Sarcoidosis |
| Clinical Trials Involving Sarcoidosis | Ongoing Trials on Sarcoidosis at Clinical Trials.gov • Trial results on Sarcoidosis • Clinical Trials on Sarcoidosis at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Sarcoidosis | US National Guidelines Clearinghouse on Sarcoidosis • NICE Guidance on Sarcoidosis • NHS PRODIGY Guidance • FDA on Sarcoidosis • CDC on Sarcoidosis |
| Textbook Information on Sarcoidosis | Books and Textbook Information on Sarcoidosis |
| Pharmacology Resources on Sarcoidosis | Dosing of Sarcoidosis • Drug interactions with Sarcoidosis • Side effects of Sarcoidosis • Allergic reactions to Sarcoidosis • Overdose information on Sarcoidosis • Carcinogenicity information on Sarcoidosis • Sarcoidosis in pregnancy • Pharmacokinetics of Sarcoidosis • |
| Genetics, Pharmacogenomics, and Proteinomics of Sarcoidosis | Genetics of Sarcoidosis • Pharmacogenomics of Sarcoidosis • Proteomics of Sarcoidosis |
| Newstories on Sarcoidosis | Sarcoidosis in the news • Be alerted to news on Sarcoidosis • News trends on Sarcoidosis |
| Commentary on Sarcoidosis | Blogs on Sarcoidosis |
| Patient Resources on Sarcoidosis | Patient resources on Sarcoidosis • Discussion groups on Sarcoidosis • Patient Handouts on Sarcoidosis • Directions to Hospitals Treating Sarcoidosis • Risk calculators and risk factors for Sarcoidosis |
| Healthcare Provider Resources on Sarcoidosis | Symptoms of Sarcoidosis • Causes & Risk Factors for Sarcoidosis • Diagnostic studies for Sarcoidosis • Treatment of Sarcoidosis |
| Continuing Medical Education (CME) Programs on Sarcoidosis | CME Programs on Sarcoidosis |
| International Resources on Sarcoidosis | Sarcoidosis en Espanol • Sarcoidosis en Francais |
| Business Resources on Sarcoidosis | Sarcoidosis in the Marketplace • Patents on Sarcoidosis |
| Informatics Resources on Sarcoidosis | List of terms related to Sarcoidosis |
| ||||
da:Sarkoidose
de:Sarkoidoseeo:Sarkoidozo
eu:Sarkoidosia
fr:Sarcoïdose
he:סרקואידוזיס
lb:Sarkoidos
nl:Sarcoïdose
ja:サルコイドーシス
no:Sarkoidose
nn:sarkoidosesq:Sarkoidoza
fi:Sarkoidoosi
sv:Sarkoidos
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

